Biosensors

Biosensors: Counter seeing renewed interest with big buying volumes after hitting its recent 52-week low of $0.82 on 26 and 29 Aug. The company has also been acquiring shares through its share buy-back scheme over Jun and Aug. CS believes the current share price weakness provides an attractive entry point with the potential on-going share buy back as downside protection. Mgmt previously indicated that it will continue to be on the lookout for M&A opportunities to grow the group into a global medical devices platform group.